Shaker Spotlight

KELLY OFMAN JOINS ABELSONTAYLOR GROUP AS VP, ACCOUNT DIRECTOR
AbelsonTaylor Group has appointed Kelly Ofman as Vice President, Account Director. Ofman brings more than 15 years of experience leading integrated pharmaceutical marketing initiatives across consumer and healthcare professional (HCP) audiences, with deep expertise in specialty and immunology brands. Ofman joins AbelsonTaylor Group from Havas Lynx / Havas Life, where she most recently served as Senior Vice President, Management Supervisor. There, she led US and global launch strategy and omnichannel execution for high-profile pharmaceutical brands, including Eisai’s LEQEMBI and Pfizer and Sumitomo’s Myfembree. “Kelly brings a powerful combination of strategic rigor, launch excellence, and deep therapeutic experience,” said Lynnette Hunter, EVP, Director of Client Services at AbelsonTaylor Group. “She understands how to connect insight to execution across audiences and channels, and she has a proven ability to lead teams and clients through some of the most complex and high-stakes moments in a brand’s lifecycle.”

Imre Appoints Paulina De la Riva as Chief Strategy Officer
Imre announced the appointment of Paulina De la Riva as Chief Strategy Officer, further strengthening the agency’s leadership team and advancing its integrated, performance-driven model. Paulina joins Imre with more than 18 years of experience spanning consumer and healthcare marketing at agencies including TBWA, McCann, and Ogilvy Health. She brings a rare, end-to-end strategic perspective that connects business ambition to brand meaning and, ultimately, to how brands show up in the market. Having started her career as a creative before evolving into a brand strategist and digital, data-driven marketing expert, Paulina has an intuitive understanding of how ideas translate from insight to execution. “Paulina is a rarity in our industry. She understands how insight, creativity, experience, data, and performance work together—and how to integrate teams so they can thrive. That integration allows us to operate in agile pods, move faster, and deliver more effective solutions to market for our clients,” said Nadine Lafond, Chief Executive Officer at Imre.

 

Mover Alert

AES Cleanroom Technology
AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, has appointed John Groth as Chief Revenue Officer. Groth brings more than 20 years of experience in pharmaceutical manufacturing technology, capital equipment sales, financial markets, and legal strategy. He joins AES from Optima, where he served as Vice President of the Pharma Division.

Ardena
Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announced the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. Ash brings more than 20 years of finance leadership experience, predominantly within the pharmaceutical sector. Zijlstra brings a strong track record in commercial leadership, brand positioning, and business development within the pharmaceutical and CDMO industry. She has held senior leadership roles across the sector, including at Lonza, and most recently at Adragos.

BioDuro
BioDuro, a leading global contract research, development, and manufacturing organization (CRDMO), announced the appointment of Andrew Thomas, PhD and Stevan Djuric, PhD as scientific advisors. In these new roles, they will provide strategic guidance to clients, and BioDuro’s scientific and operational teams, helping strengthen the company’s capabilities in innovative drug discovery and development. Both advisors bring decades of global pharmaceutical R&D leadership experience and are already actively engaged in supporting BioDuro’s customers’ programs.

Biologos
Biologos, a leading ISO 13485–certified and GMP-compliant manufacturer of custom sterilefiltered liquid solutions, today announced the appointment of Hetal Patel as Chief Executive Officer. The announcement coincides with Biologos’ 50th anniversary and follows significant recent investments in facilities and capabilities to support customers across biopharma, cell and gene therapy (CGT), tissue processing, and animal health markets.

DeepIntent
DeepIntent has appointed Ian Colley as Chief Marketing Officer (CMO). Colley will lead the company’s global brand, marketing, and communications strategy. Colley brings nearly 30 years of experience scaling high-performing marketing and communications organizations across leading technology companies. He most recently served as the CMO at The Trade Desk where he led all aspects of global marketing, communications, editorial content, and more. Previously, he spent more than 20 years leading communications at IBM.

Deerfield Group
Deerfield Group, a leading integrated marketing, communications, and media partner for the healthcare and life sciences sectors, announced the promotion of Bill Veltre to Chief Media Officer (CMO). Previously serving as Executive Vice President and Head of Media, Veltre’s elevation to the C-Suite reflects the agency’s strategic commitment to media as a critical, deeply integrated capability for client success across the full healthcare life cycle.

GC Therapeutics (GCTx)
GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cellbased medicines through its TFomeTM (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) programming platform, has appointed Stefan Irion, MD as Chief Scientific Officer. Dr. Irion brings more than two decades of experience translating stem cell science into clinical stage therapeutics. In his role at GCTx, Dr. Irion will lead and direct the company’s research strategy as it advances its differentiated cell therapy pipeline toward the clinic.

Inimmune Corporation
Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, announced the appointments of Ferdinand Massari, MD as Chief Medical Officer (CMO), and Ryan McMillian as Head of Financial Strategy. The appointments strengthen the leadership team as Inimmune advances its lead allergic rhinitis program, INI-2004, toward key milestones and planned expansion into allergic asthma and food allergy.

The Quantitative Biosciences Institute (QBI)
The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) has appointed John A.T. Young, PhD as Chief Strategy Officer. Dr. Young brings over three decades of experience spanning academic research, pharmaceutical R&D leadership, and global public health, making him uniquely positioned to advance QBI’s mission of translating cuttingedge protein-protein interaction (PPI) science into transformative therapies. Dr. Young joins QBI from Roche Pharma Research and Early Development (pRED).

Sygnature Discovery
Sygnature Discovery, a leading integrated drug discovery contract research organization (CRO), has announced the appointment of Susanne Back as Head of In Vivo Pharmacology, further strengthening its bioscience leadership and reinforcing its commitment to delivering high-quality, integrated drug discovery solutions for customers worldwide. Susanne brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River.